CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
IntroductionThe combination of Myc-suppressed whole tumor cells with checkpoint inhibitors targeting CTLA-4 and PD-L1 generates a potent therapeutic cancer vaccine in a mouse neuroblastoma model. As immunotherapies translate from pre-clinical to clinical trials, the potential immune-related adverse...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1176370/full |
| _version_ | 1797810501816680448 |
|---|---|
| author | Xiaofang Wu Priya Srinivasan Mousumi Basu Talia Zimmerman Samuel Li Yin Wang Pan Zheng Yang Liu Anthony David Sandler |
| author_facet | Xiaofang Wu Priya Srinivasan Mousumi Basu Talia Zimmerman Samuel Li Yin Wang Pan Zheng Yang Liu Anthony David Sandler |
| author_sort | Xiaofang Wu |
| collection | DOAJ |
| description | IntroductionThe combination of Myc-suppressed whole tumor cells with checkpoint inhibitors targeting CTLA-4 and PD-L1 generates a potent therapeutic cancer vaccine in a mouse neuroblastoma model. As immunotherapies translate from pre-clinical to clinical trials, the potential immune-related adverse events (irAEs) associated with induction of potent immunity must be addressed. The CD24-Siglec 10/G interaction is an innate checkpoint that abrogates inflammatory responses to molecules released by damaged cells, but its role in cancer immunology is not well defined. We investigate irAEs of an effective whole cell neuroblastoma vaccine and subsequently the effect of CD24-Fc, a CD24 and Fc fusion protein, on both the vaccine efficacy and induced irAEs in a mouse neuroblastoma model.MethodsTo test whether the whole tumor cell vaccination leads to autoimmune responses in other organ systems we harvested lung, heart, kidney and colon from naïve mice (n=3), unvaccinated tumor only mice (n=3), and vaccinated mice with CD24 Fc (n=12) or human IgG-Fc control (n=12) after tumor inoculation and vaccination therapy at day 30. The Immune cell infiltrates and immunogenic pathway signatures in different organ systems were investigated using NanoString Autoimmune Profiling arrays. Nanostring RNA transcript results were validated with immunohistochemistry staining.ResultsThe whole tumor cell vaccine combined with immune checkpoint therapy triggers occult organ specific immune cell infiltrates, primarily in cardiac tissue and to a lesser extent in the renal and lung tissue, but not in the colon. CD24-Fc administration with vaccination partially impedes anti-tumor immunity but delaying CD24-Fc administration after initial vaccination reverses this effect. CD24-Fc treatment also ameliorates the autoimmune response induced by effective tumor vaccination in the heart.DiscussionThis study illustrates that the combination of Myc suppressed whole tumor cell vaccination with checkpoint inhibitors is an effective therapy, but occult immune infiltrates are induced in several organ systems in a mouse neuroblastoma model. The systemic administration of CD24-Fc suppresses autoimmune tissue responses, but appropriate timing of administration is critical for maintaining efficacy of the therapeutic vaccine. |
| first_indexed | 2024-03-13T07:08:51Z |
| format | Article |
| id | doaj.art-9fd0de311e1d451aab33cc9cd3b3d71e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-13T07:08:51Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-9fd0de311e1d451aab33cc9cd3b3d71e2023-06-06T04:52:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-06-011410.3389/fimmu.2023.11763701176370CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastomaXiaofang Wu0Priya Srinivasan1Mousumi Basu2Talia Zimmerman3Samuel Li4Yin Wang5Pan Zheng6Yang Liu7Anthony David Sandler8The Joseph E. Robert Jr. Center for Surgical Care and The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, George Washington University, Washington, DC, United StatesThe Joseph E. Robert Jr. Center for Surgical Care and The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, George Washington University, Washington, DC, United StatesThe Joseph E. Robert Jr. Center for Surgical Care and The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, George Washington University, Washington, DC, United StatesThe Joseph E. Robert Jr. Center for Surgical Care and The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, George Washington University, Washington, DC, United StatesThe Joseph E. Robert Jr. Center for Surgical Care and The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, George Washington University, Washington, DC, United StatesUniversity of Maryland Medical Center, University of Maryland, Baltimore, MD, United StatesOncoC4. Inc, Rockville, MD, United StatesOncoC4. Inc, Rockville, MD, United StatesThe Joseph E. Robert Jr. Center for Surgical Care and The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Hospital, George Washington University, Washington, DC, United StatesIntroductionThe combination of Myc-suppressed whole tumor cells with checkpoint inhibitors targeting CTLA-4 and PD-L1 generates a potent therapeutic cancer vaccine in a mouse neuroblastoma model. As immunotherapies translate from pre-clinical to clinical trials, the potential immune-related adverse events (irAEs) associated with induction of potent immunity must be addressed. The CD24-Siglec 10/G interaction is an innate checkpoint that abrogates inflammatory responses to molecules released by damaged cells, but its role in cancer immunology is not well defined. We investigate irAEs of an effective whole cell neuroblastoma vaccine and subsequently the effect of CD24-Fc, a CD24 and Fc fusion protein, on both the vaccine efficacy and induced irAEs in a mouse neuroblastoma model.MethodsTo test whether the whole tumor cell vaccination leads to autoimmune responses in other organ systems we harvested lung, heart, kidney and colon from naïve mice (n=3), unvaccinated tumor only mice (n=3), and vaccinated mice with CD24 Fc (n=12) or human IgG-Fc control (n=12) after tumor inoculation and vaccination therapy at day 30. The Immune cell infiltrates and immunogenic pathway signatures in different organ systems were investigated using NanoString Autoimmune Profiling arrays. Nanostring RNA transcript results were validated with immunohistochemistry staining.ResultsThe whole tumor cell vaccine combined with immune checkpoint therapy triggers occult organ specific immune cell infiltrates, primarily in cardiac tissue and to a lesser extent in the renal and lung tissue, but not in the colon. CD24-Fc administration with vaccination partially impedes anti-tumor immunity but delaying CD24-Fc administration after initial vaccination reverses this effect. CD24-Fc treatment also ameliorates the autoimmune response induced by effective tumor vaccination in the heart.DiscussionThis study illustrates that the combination of Myc suppressed whole tumor cell vaccination with checkpoint inhibitors is an effective therapy, but occult immune infiltrates are induced in several organ systems in a mouse neuroblastoma model. The systemic administration of CD24-Fc suppresses autoimmune tissue responses, but appropriate timing of administration is critical for maintaining efficacy of the therapeutic vaccine.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1176370/fullCD24Fctumor cell vaccineneuroblastomaimmune-related adverse eventsautoimmune profiling |
| spellingShingle | Xiaofang Wu Priya Srinivasan Mousumi Basu Talia Zimmerman Samuel Li Yin Wang Pan Zheng Yang Liu Anthony David Sandler CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma Frontiers in Immunology CD24Fc tumor cell vaccine neuroblastoma immune-related adverse events autoimmune profiling |
| title | CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma |
| title_full | CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma |
| title_fullStr | CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma |
| title_full_unstemmed | CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma |
| title_short | CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma |
| title_sort | cd24 fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma |
| topic | CD24Fc tumor cell vaccine neuroblastoma immune-related adverse events autoimmune profiling |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1176370/full |
| work_keys_str_mv | AT xiaofangwu cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma AT priyasrinivasan cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma AT mousumibasu cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma AT taliazimmerman cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma AT samuelli cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma AT yinwang cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma AT panzheng cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma AT yangliu cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma AT anthonydavidsandler cd24fcsuppressionofimmunerelatedadverseeventsinatherapeuticcancervaccinemodelofmurineneuroblastoma |